UCB SA (0NZT.L)

81.40 -2.18 (-2.60%) At close: 06:19PM BST

UCB SA

Allée de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Sector(s): 
Industry: 
Full-time employees: 8,450

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jean-Christophe Tellier	CEO & Executive Director	4.1M	N/A	1959
Ms. Sandrine Dufour CFA	Executive VP, CFO & Chief Corporate Development	N/A	N/A	1966
Dr. Kirsten Lund-Jurgensen Ph.D.	Executive Vice President of Supply & Technology Solutions	N/A	N/A	1960
Dr. Dhavalkumar D. Patel M.D., Ph.D.	Executive VP & Chief Scientific Officer	N/A	N/A	1961
Ms. Denelle J. Waynick Johnson J.D.	Executive VP & General Counsel	N/A	N/A	1967
Mr. Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	N/A	N/A	1965
Prof. Iris Low-Friedrich	Executive VP & Chief Medical Officer	N/A	N/A	1960
Mr. Emmanuel Caeymaex	Executive VP of Immunology Solutions & Head of US	N/A	N/A	1969
Ms. Caroline Vancoillie	Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions	N/A	N/A	N/A
Antje Witte	Head of Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Corporate governance

UCB SA’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.